Enhanced dissolution and oral bioavailability of valsartan solid dispersions prepared by a freeze-drying technique using hydrophilic polymers

References

• Bikiaris D, Papageorgiou GZ, Stergiou A, et al. (2005). Physicochemical studies on solid dispersions of poorly water-soluble drugs: evaluation of capabilities and limitations of thermal analysis techniques. Thermochim Acta 439:58–67
   Web of Science ®Google Scholar
• Cao QR, Liu Y, Xu WJ, et al. (2012). Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique. Int J Pharm 434:325–33
   PubMed Web of Science ®Google Scholar
• Chawla G, Gupta P, Thilagavathi R, et al. (2003). Characterization of solid-state forms of celecoxib. Eur J Pharm Sci 20:305–17
   PubMed Web of Science ®Google Scholar
• Criscione L, De Gasparo M, Buhlmayer P, et al. (1993). Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 110:761–71
   PubMed Web of Science ®Google Scholar
• Dai WG, Dong LC, Song YQ. (2007). Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int J Pharm 342:201–7
   PubMed Web of Science ®Google Scholar
• Dina R, Jafari M. (2000). Angiotensin II – receptor antagonist: an overview. Am J Health Syst Pharm 57:1231–40
   PubMed Web of Science ®Google Scholar
• Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. (2006). A review of poloxamer407 pharmaceutical and pharmacological characteristics. Pharmacol Res 23:2709–28
   Web of Science ®Google Scholar
• Flesch G, Muller PH, Lloyd P. (1997). Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52:115–20
   PubMed Web of Science ®Google Scholar
• Huang YB, Tsai YH, Yang WC, et al. (2004). Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm 58:607–14
   PubMed Web of Science ®Google Scholar
• Israili ZH. (2000). Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14:S73–86
   PubMed Web of Science ®Google Scholar
• Joe JH, Lee WM, Park YJ, et al. (2010). Effect of the solid-dispersion method on the solubility and crystalline property Tacrolimus. Int J Pharm 395:161–6
   PubMed Web of Science ®Google Scholar
• Kim EJ, Chun MK, Jang JS, et al. (2006). Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur J Pharm Biopharm 64:200–5
   PubMed Web of Science ®Google Scholar
• Koester LS, Mayorga P, Bassani VL. (2003). Carbamazepine/βCD/HPMC Solid Dispersions. I. Influence of the spray-drying process and βCD/HPMC on the drug dissolution profile. Drug Dev Ind Pharm 29:139–44
   PubMed Web of Science ®Google Scholar
• Lee S, Nam K, Kim MS, et al. (2005). Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch Pharm Res 28:866–74
   PubMed Web of Science ®Google Scholar
• Marasini N, Tran TH, Poudel BK, et al. (2013). Fabrication and evaluation of pH-modulated solid dispersion spray-drying technique. Int J Pharm 441:424–32
   PubMed Web of Science ®Google Scholar
• Mbah CJ. (2005). Physicochemical properties of valsartan and the effect of ethyl alcohol, propylene glycol and pH on its solubility. Pharmazie 60:849–50
   PubMed Web of Science ®Google Scholar
• Miller DA, McConville JT, Yang W, et al. (2007). Hot-melt extrusion for enhanced delivery of drug particles. J Pharmacol Sci 96:361–76
   PubMed Web of Science ®Google Scholar
• Mura P, Cirri M, Faucci MT, et al. (2002). Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J Pharm Biomed Anal 30:227–37
   PubMed Web of Science ®Google Scholar
• Mura P, Moyano J, González-Rodríguez M, et al. (2005). Characterization and dissolution properties of ketoprofen in binary and ternary solid dispersions with polyethylene glycol and surfactants. Drug Dev Ind Pharm 31:425–34
   PubMed Web of Science ®Google Scholar
• Palmieri GF, Cantalamessa F, Di Martino P, et al. (2002). Lonidamine solid dispersions: in vitro and in vivo evaluation. Drug Dev Ind Pharm 28:1241–50
   PubMed Web of Science ®Google Scholar
• Purvis T, Vaughn JM, Rogers TL, et al. (2006). Cryogenic liquids, nanoparticles, and microencapsulation. Int J Pharm 324:43–50
   PubMed Web of Science ®Google Scholar
• Riis T, Bauer-Brandl A, Wagner T, Kranz H. (2007). pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Eur J Pharm Biopharm 65:78–84
   PubMed Web of Science ®Google Scholar
• Tran PHL, Tran HTT, Lee BJ. (2008). Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J Control Release 129:59–65
   PubMed Web of Science ®Google Scholar
• Tran TTD, Tran PHL, Lee BJ. (2009). Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug. Eur J Pharm Biopharm 72:83–90
   PubMed Web of Science ®Google Scholar
• Tsinontides SC, Rajniak P, Pham D, et al. (2004). Freeze drying-principles and practice for successful scale-up to manufacturing. Int J Pharm 280:1–16
   PubMed Web of Science ®Google Scholar
• Van den Mooter G, Weuts I, De Ridder T, Blaton N. (2006). Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int J Pharm 316:1–6
   PubMed Web of Science ®Google Scholar
• Vlachou M, Hani N, Efentakis M, et al. (2000). Polymers for use in controlled release systems: the effect of surfactants on their swelling properties. J Biomater Appl 15:65–77
   PubMed Web of Science ®Google Scholar
• Yamashita K, Nakate T, Okimoto K, et al. (2003). Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 267:79–91
   PubMed Web of Science ®Google Scholar
• Yan YD, Sung JH, Kim KK, et al. (2012). Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Int J Pharm 422:202–10
   PubMed Web of Science ®Google Scholar
• Yu J, Chun MK, Choi HK. (2007). Preparation and characterization of piroxicam/poloxamer solid dispersion prepared by melting method and solvent method. J Kor Pharm Sci 37:1–5
   Google Scholar
• Zerrouk N, Chemtob C, Arnaud P, et al. (2001). In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int J Pharm 225:49–62
   PubMed Web of Science ®Google Scholar